Abstract

The present invention relates to a lipid-based formulation for topical ophthalmic use to increase the bioavailability of antibiotics in intraocular tissues, wherein said formulation comprises: Moxifloxacin (M), polyethylene glycol (PEG)-12 glyceryl dimyristate and ethyl alcohol, polyethylene glycol (15)-hydroxystearate (Kolliphor® HS15), anhydrous citric acid and sodium citrate dihydrate. The compositions of the invention contain an effective amount of moxifloxacin (M), 0.001 to 1 mg, in other words, 0.0001 to 0.1% (w/v), polyethylene glycol (PEG)-12 glyceryl dimyristate which is used as a structural component of liposomes in a concentration of 5-15% (w/v) and ethyl alcohol which is used as an organic solvent in a concentration of 0.7 to 2.1% (v/v). Furthermore, the formulation contains 2.5 to 7.5% (w/v) of polyethylene glycol (15)-hydroxystearate (Kolliphor® HS15) as a non-ionic solubiliser and emulsifying agent. Likewise, the aqueous compositions of the present invention optionally comprise more excipients selected from the group consisting of buffering agents, pH-adjusting agents and preservatives. Anhydrous citric acid (0.04 to 0.16%) and sodium citrate dihydrate (0.23 to 0.69%) are used as buffers.

IPC Classes  ?

• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61P 27/02 - Ophthalmic agents

Abstract

The invention relates to a lipid-based formulation that increases the penetration of the eyeball by anaesthetics for topical ophthalmic use, wherein the formulation comprises: tetracaine (T), polyethylene glycol (PEG)-12 glyceryl dimyristate, ethyl alcohol, PEG(15)-hydroxystearate (Kolliphor® HS15), citric acid anhydride and sodium citrate dihydrate. The compound of the invention is characterised by low toxicity and in that it also acts as a permeability enhancer because it promotes molecule transport through the cell membranes, increasing the endocytosis rate and stimulating drug translocation via the paracellular route.

IPC Classes  ?

• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61P 27/02 - Ophthalmic agents
• A61P 23/00 - Anaesthetics

Abstract

The present invention relates to a lipid-based formulation for topical ophthalmic use to increase the bioavailability of non-steroidal anti-inflammatory drugs in intraocular tissues that comprises an effective amount of a non-steroidal anti-inflammatory drug (NSAID), polyethylene glycol (PEG)-12 glyceryl dimyristate, polyethylene glycol (15)-hydroxystearate (Kolliphor® HS15), an organic solvent, and excipients selected from the group consisting of buffering agents.

IPC Classes  ?

• A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61P 27/02 - Ophthalmic agents
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to a lipid-based formulation for topical ophthalmic use that acts as a liposomal system for the delivery of helenalin to the scleral tissue of the ocular surface (cornea and conjunctiva) in human beings. The invention is useful for treating dry eye syndrome (DES) owing to its anti-inflammatory activity and its ability to inhibit the action of tumour necrosis factor-alpha (TNFα) and metalloproteinase 9 (MMP-9). The lipid-based formulation has the potential to improve stability, enhance the efficiency of penetration of the natural barriers of the eyeball and increase helenalin bioavailability in the tissues of the ocular surface.

IPC Classes  ?

• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 27/02 - Ophthalmic agents

Abstract

The invention relates to a solution for enhancing the efficiency of the penetration and bioavailability of bioactives present in jaborandi extract in the scleral tissue of the eye ball, which is based on using advanced delivery systems and methods, such as lipid-based systems. Some of these lipid systems include lipid, micellar and liposome nanoparticles. The lipid nanoparticles are aqueous colloidal dispersions comprising solid lipids as matrix material, capable of encapsulating both hydrophilic and lipophilic agents, which ultimately yield thermodynamically stable compounds, with the encapsulated agent being protected. The compounds have controlled release and are biocompatible with the barriers of the eye ball, easy to produce and able to be sterilised in an autoclave. Accordingly, the lipid-based topical ophthalmic formulation comprising jaborandi extract represents an important advancement in enhancing the efficiency of the penetration and bioavailability of the bioactives thereof in scleral tissue (iris and lens) of the human eyeball.

IPC Classes  ?

• A61K 36/75 - Rutaceae (Rue family)
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 27/02 - Ophthalmic agents

Abstract

Method and chemical formulation for treating contaminated medical waste by means of grinding and disinfection with peracetic acid. The invention relates to a peracetic-acid-based formulation and a continuous in-situ method for grinding and disinfecting, with the peracetic acid formulation, medical waste contaminated with viruses, bacteria, etc.

IPC Classes  ?

• B09B 3/35 - Shredding, crushing or cutting
• A01N 37/16 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group Thio-analogues thereof
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• B09B 3/60 - Biochemical treatment, e.g. by using enzymes
• B09B 101/65 - Medical waste

Abstract

Vaccinium Myrtillus LVaccinium Myrtillus L), omega-3 fatty acids, lactoferrin, vitamins A and E and excipients with surfactant properties, for primary treatment and/or as an adjuvant for dry eye syndrome in human beings. In order to overcome the negative aspects of administering the formulation individually and to provide synergistic effects, the invention is characterised by the design of a formulation containing, among other components, polyphenols from blueberry extract, without eliminating the matrix, which promotes the bioactivity of the polyphenols present in same, as there is evidence that the presence of other polyphenols increases the bioavailability and bioactivity thereof. In addition, other elements of the matrix promote stability and absorption of polyphenols.

IPC Classes  ?

• A61K 31/07 - Retinol compounds, e.g. vitamin A
• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 27/02 - Ophthalmic agents

Abstract

The invention consists of a food supplement based on a mixture of nopal, cacao and cricket contained preferably, but not exclusively, in sachets, for its primary use as an adjuvant for managing insulin resistance, reducing intestinal dysbiosis and reducing obesity in patients with some type of obesity and/or suffering from fatty liver disease of any aetiology, Crohn's disease or any other intestinal metabolic disorder. Furthermore, the food supplement can also be mixed with any type of prebiotics and/or probiotics, for its use as an adjuvant for managing malnutrition, obesity, dysbiosis and insulin resistance in patients with any type of obesity and/or suffering from fatty liver disease.

IPC Classes  ?

• A61K 35/64 - Insects, e.g. bees, wasps or fleas
• A61K 36/33 - Cactaceae (Cactus family), e.g. pricklypear or Cereus
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61P 3/04 - AnorexiantsAntiobesity agents

Abstract

Arnica montanaArnica montana extract and sodium hyaluronate for use to treat dry eye syndrome. The formulation improves tear film quality and modulates the inflammatory process and the symptoms associated with dry eye syndrome.

IPC Classes  ?

• A61K 36/28 - Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
• A61K 31/728 - Hyaluronic acid
• A61P 27/02 - Ophthalmic agents

Abstract

The invention relates to a lipid-based formulation for topical ophthalmic use that acts as a liposomal system for the delivery of bioactive agents contained in peppermint leaf extract to the scleral tissue of the posterior segment of the eyeball in humans. The invention is useful for maintaining health and reducing the risk of the development of chronic degenerative processes in the intraocular tissues, including those of the posterior segment of the eyeball, owing to its anti-inflammatory, antiangiogenic, antifibrotic and antioxidant activity. The lipid-based formulation has the potential to improve stability, boost the efficiency of penetration of the natural barriers of the eyeball and increase polyphenol bioavailability in the intraocular tissues.

IPC Classes  ?

• A61K 36/534 - Mentha (mint)
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 27/02 - Ophthalmic agents

Abstract

Disclosed is a formulation which, in association with a grinding system, transforms biohazardous wastes unto raw material for the preparation of composts, enabling biohazardous infectious waste to be inactivated for use and industrial biohazardous infectious waste to be inactivated for reuse as a protein source for producing protein products. The formulation can be used to eliminate microorganisms in waste resulting from the production of drugs and vaccines in ovo, with applications in biohazardous infectious waste and animal waste with a high protein content and decomposition potential for the preparation of composts.

IPC Classes  ?

• A61L 11/00 - Disinfection or sterilising methods specially adapted for refuse
• A01N 37/16 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group Thio-analogues thereof
• A61L 2/18 - Liquid substances
• B09B 3/35 - Shredding, crushing or cutting
• B09B 3/70 - Chemical treatment, e.g. pH adjustment or oxidation
• C05F 7/00 - Fertilisers from waste water, sewage sludge, sea slime, ooze or similar masses
• C05F 1/00 - Fertilisers made from animal corpses, or parts thereof

Abstract

The invention relates to a lipid-based formulation for topical ophthalmic use that acts as a liposomal system for the delivery of bioactive agents contained in blueberry extract, in scleral tissue of the rear portion of the eyeball in human beings. The invention is useful for maintaining health and reducing the risk of the development of chronic degenerative processes in the intraocular tissues, including those of the rear portion of the eyeball, owing to its anti-inflammatory, antiangiogenic, anti-fibrotic and antioxidant activity. The lipid-based formulation has the potential to improve stability, improve the efficiency of penetration of the natural barriers of the eyeball and increase polyphenol bioavailability in the intraocular tissues.

IPC Classes  ?

• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 27/02 - Ophthalmic agents

Abstract

The invention consists of a lipid-based formulation for topical ophthalmic use which functions as a delivery system for the bioactive agents contained in the hop flower extract in white tissue in the rear segment of the eyeball in humans. The invention is useful for maintaining health and reducing the risk of developing chronic-degenerative processes in the intraocular tissue, including the tissue in the rear segment of the eyeball, due to its anti-inflammatory, neuro-protective and antioxidant activity. The object of this invention is to make available a lipid-based formulation for topical ophthalmic use which functions as a delivery system for the bioactive agents contained in the hop flower extract in white tissue in the rear segment of the eyeball in humans. The invention is useful for maintaining health and reducing the risk of developing chronic-degenerative processes in the intraocular tissue, including the tissue in the rear segment of the eyeball, due to its anti-inflammatory, neuro-protective and antioxidant activity.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 27/02 - Ophthalmic agents

Abstract

Method and chemical formulation for treating contaminated medical waste by means of grinding and disinfection with peracetic acid. The invention relates to a peracetic-acid-based formulation and a continuous in-situ method for grinding and disinfecting, with the peracetic acid formulation, medical waste contaminated with viruses, bacteria, etc.

IPC Classes  ?

• A01N 37/16 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group Thio-analogues thereof
• A61L 11/00 - Disinfection or sterilising methods specially adapted for refuse
• B02C 19/00 - Other disintegrating devices or methods
• B09B 3/00 - Destroying solid waste or transforming solid waste into something useful or harmless

Abstract

Described is a symbiotic formulation for the oral consumption of probiotics and prebiotics with an aqueous extract of roselle, with vitamins and proteins for humans. The invention belongs to the field of nutrition and has been developed to help to maintain a healthy digestive system by restoring and/or improving the intestinal microbiota. The purpose of the antioxidants and the synergic effect of the symbiotic formulation is to reduce the inflammatory process so as to facilitate the absorption of nutrients and thus improve the good nutritional state of people. An oral symbiotic formulation based on an aqueous roselle extract with encapsulated probiotics and which can contribute to the consumption of antioxidants of natural origin, the ingestion of proteins and micronutrients for re-establishing or improving the state of the intestinal microbiota, as well as the nutritional state of adults and older people, has not been found in the prior art.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/733 - Fructosans, e.g. inulin
• A61K 35/747 - Lactobacilli, e.g. L. acidophilus or L. brevis
• A61K 35/745 - Bifidobacteria
• A61K 31/4172 - Imidazole-alkanecarboxylic acids, e.g. histidine
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 31/4415 - Pyridoxine, i.e.vitamin B6
• A61K 31/714 - Cobalamins, e.g. cyanocobalamin, vitamin B12
• A61K 31/525 - Isoalloxazines, e.g. riboflavins, vitamin B2
• A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/07 - Retinol compounds, e.g. vitamin A
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/51 - Thiamines, e.g. vitamin B1
• A61K 31/355 - Tocopherols, e.g. vitamin E
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/175 - Amino acids
• A23L 33/16 - Inorganic salts, minerals or trace elements
• A23L 33/155 - Vitamins A or D
• A23L 33/22 - Comminuted fibrous parts of plants, e.g. bagasse or pulp

Abstract

Disclosed is a formulation which, associated with a grinding system, transforms biohazardous infectious waste (RPBI) into raw material for producing compost, allowing biohazardous infectious waste to be inactivated for use and industrial biohazardous infectious waste to be inactivated for reuse as a protein source for producing protein products. The formulation can be used to eliminate microorganisms in waste resulting from the production of drugs and vaccines in ovo, with applications in biohazardous infectious waste and animal waste with a high protein content and decomposition potential, for compost production.

IPC Classes  ?

• A61L 2/18 - Liquid substances
• A61L 11/00 - Disinfection or sterilising methods specially adapted for refuse
• A01N 31/02 - Acyclic compounds

Abstract

The present invention relates to the field of medicaments that reduce cardiac fibrosis and also the expression of troponin I, specifically to the pharmaceutical use containing 5-methyl-1-phenyl-2-(1H)-pyridone (Pirfenidone) as an active ingredient, alone or in combination with any other bioactive molecule, specifically for the management of patients with cardiomyopathy and/or cardiac steatosis and/or COVID-19.

IPC Classes  ?

• A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
• A61P 9/00 - Drugs for disorders of the cardiovascular system

Abstract

Diabetes is a disease characterized by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Edema (DME), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

IPC Classes  ?

• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• G06T 3/40 - Scaling of whole images or parts thereof, e.g. expanding or contracting
• G06T 3/60 - Rotation of whole images or parts thereof

Abstract

Gastritis is the inflammation of the gastric mucosa. It affects around 50% of the world population and its main etiology is the chronic consumption of non-steroidal anti-inflammatories and infection by Helicobacter pylori, in addition to an increase in acid-secreting cells. This gastric disease is characterised by the presence of polymorphonuclear cell infiltrate; an overexpression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNFa), interleukin 1 beta (IL-1b), interleukin 6 (IL-6); and hyperactivity of cyclooxygenase 2 (COX-2) and its downstream product prostaglandin E2 (PGE2), which causes inflammation in the stomach. The invention developed aims to provide a supplement of capsaicin and sulforaphane in combination with any type of prebiotics and/or probiotics, preferably contained in a capsule for use as an anti-inflammatory, anti-fibrotic, and analgesic coadjuvant for inflammation of the gastric mucosa, gastritis caused by different agents.

IPC Classes  ?

• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/26 - Cyanate or isocyanate estersThiocyanate or isothiocyanate esters
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives

Abstract

The invention relates to a pharmaceutical composition for the treatment of diseases that occur with fibrosis in any type of tissue, comprising a gene vector containing the construct including an shRNA for regulating the expression of cannabinoid receptor type-1 (CB1) as an anti-fibrotic strategy.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Abstract

Vaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film. No formulation for oral administration of a blueberry extract together with lactoferrin, in combination with vitamin A, vitamin E and fish oil (eicosapentaenoic acid and docosahexaenoic acid) is found in the prior art, nor is the use of this formulation as an adjuvant for preserving the health of the precorneal film and/or the eye surface.

IPC Classes  ?

• A23L 33/19 - Dairy proteins
• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/12 - Fatty acids or derivatives thereof
• A23L 33/155 - Vitamins A or D

Abstract

Described is a symbiotic formulation for the oral consumption of probiotics and prebiotics with an aqueous extract of roselle, with vitamins and proteins for humans. The invention belongs to the field of nutrition and has been developed to help to maintain a healthy digestive system by restoring and/or improving the intestinal microbiota. The purpose of the antioxidants and the synergic effect of the symbiotic formulation is to reduce the inflammatory process so as to facilitate the absorption of nutrients and thus improve the good nutritional state of people. An oral symbiotic formulation based on an aqueous roselle extract with encapsulated probiotics and which can contribute to the consumption of antioxidants of natural origin, the ingestion of proteins and micronutrients for re-establishing or improving the state of the intestinal microbiota, as well as the nutritional state of adults and older people, has not been found in the prior art.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23L 33/15 - Vitamins

Abstract

The purpose of the invention is to provide the use of 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone) and chitosan in an ophthalmic solution for preventing the development of corneal opacity following refractive ophthalmic surgery with an excimer laser. Every 100 mL of the ophthalmic solution contains 0.1-1.5 g pirfenidone, 0.5-2 g chitosan, 0.5 g povidone, 5 g Kolliphor® HS 15, 0.6-0.62 g boric acid, 0.5-0.9 g sodium chloride, 0.5 g chlorobutanol and injectable water. The pH of the ophthalmic solution is 6.5-7. On the basis of the experiments conducted on the developed formulation, it is observed that both chitosan plus pirfenidone, and prednisolone are able to reverse corneal damage once corneal damage has been established.

IPC Classes  ?

• A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/722 - ChitinChitosan
• A61P 27/02 - Ophthalmic agents

Abstract

Diabetes is a disease characterised by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Oedema (DMO), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume

Abstract

322244). The formulation obtained can be applied to infectious, hazardous biological residues in hospital waste, medical devices without metal parts, haemodialysis filters, laser crystal tips, medical instruments made from plastic, elastomers and stainless steel, water treatment, food handling and hygiene, disinfection of grey and white areas in hospitals, laboratories and clinics, disinfection of fruit and vegetables. As such, the range of application of the formulation is broad.

IPC Classes  ?

• A01N 37/16 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group Thio-analogues thereof
• A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor using chemical substances
• A61K 8/22 - PeroxidesOxygenOzone

Abstract

Vaccinium myrtillus LVaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film. No formulation for oral administration of a blueberry extract together with lactoferrin, in combination with vitamin A, vitamin E and fish oil (eicosapentaenoic acid and docosahexaenoic acid) is found in the prior art, nor is the use of this formulation as an adjuvant for preserving the health of the precorneal film and/or the eye surface.

IPC Classes  ?

• A61K 31/07 - Retinol compounds, e.g. vitamin A
• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61P 27/02 - Ophthalmic agents

Abstract

The invention relates to a nutraceutical formulation of blueberry extract, fish oil (omega-3 and omega-6), recombinant human lactoferrin, vitamin A and vitamin E, for human oral consumption. The invention belongs to the field of ophthalmology and has been developed as a coadjuvant for preserving the health of the precorneal film and of the eye surface. This formulation contains an extract of natural origin (Vaccinium myrtillus L) with antioxidant and anti-inflammatory properties; it also uses eicosapentaenoic acid (EPA), omega-6, and docosahexaenoic acid (DHA), omega-3, obtained from fish oil and which, together with lactoferrin, vitamin A and vitamin E, improves tear quality, since these compounds have anti-microbial and anti-inflammatory effects. This formulation has been designed as a coadjuvant for preserving the health of the precorneal film. No formulation for oral administration of a blueberry extract together with lactoferrin, in combination with vitamin A, vitamin E and fish oil (eicosapentaenoic acid and docosahexaenoic acid) is found in the prior art, nor is the use of this formulation as an adjuvant for preserving the health of the precorneal film and/or the eye surface.

IPC Classes  ?

• A61K 31/07 - Retinol compounds, e.g. vitamin A
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 36/45 - Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
• A61P 27/02 - Ophthalmic agents